Institute of Biomedical Research, Immunity and Infection Department, Birmingham University School of Medical and Dental Science, Edgbaston, Birmingham, UK.
Leukemia. 2013 Mar;27(3):661-70. doi: 10.1038/leu.2012.241. Epub 2012 Aug 22.
The haematopoietic system is prone to age-related disorders ranging from deficits in functional blood cells to the development of neoplastic states. Such neoplasms often involve recurrent cytogenetic abnormalities, among which a deletion in the long arm of chromosome 20 (del20q) is common in myeloid malignancies. The del20q minimum deleted region contains nine genes, including MYBL2, which encodes a key protein involved in the maintenance of genome integrity. Here, we show that mice expressing half the normal levels of Mybl2 (Mybl2(+/Δ)) develop a variety of myeloid disorders upon ageing. These include myeloproliferative neoplasms, myelodysplasia (MDS) and myeloid leukaemia, mirroring the human conditions associated with del20q. Moreover, analysis of gene expression profiles from patients with MDS demonstrated reduced levels of MYBL2, regardless of del20q status and demonstrated a strong correlation between low levels of MYBL2 RNA and reduced expression of a subset of genes related to DNA replication and checkpoint control pathways. Paralleling the human data, we found that these pathways are also disturbed in our Mybl2(+/Δ) mice. This novel mouse model, therefore, represents a valuable tool for studying the initiation and progression of haematological malignancies during ageing, and may provide a platform for preclinical testing of therapeutic approaches.
造血系统容易发生与年龄相关的疾病,从功能性血液细胞的缺陷到肿瘤状态的发展。这种肿瘤通常涉及反复的细胞遗传学异常,其中 20 号染色体长臂缺失(del20q)在髓系恶性肿瘤中很常见。del20q 最小缺失区域包含九个基因,包括编码参与基因组完整性维持的关键蛋白的 MYBL2。在这里,我们表明表达正常水平一半的 Mybl2(Mybl2(+/Δ))的小鼠在衰老时会发展出各种髓系疾病。这些疾病包括骨髓增生性肿瘤、骨髓增生异常(MDS)和髓系白血病,与人类与 del20q 相关的疾病相吻合。此外,对 MDS 患者的基因表达谱分析表明,无论 del20q 状态如何,MYBL2 的水平都降低,并表明 MYBL2 RNA 水平低与与 DNA 复制和检查点控制途径相关的一组基因的表达降低之间存在很强的相关性。与人类数据平行,我们发现这些途径在我们的 Mybl2(+/Δ) 小鼠中也受到干扰。因此,这种新型小鼠模型是研究衰老过程中血液恶性肿瘤的发生和进展的有价值的工具,并且可能为临床前测试治疗方法提供平台。